Clinical Trials Logo

Clinical Trial Summary

This is Phase 1 and 2a, Multi-center, Open-label study designed to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID vaccine in Healthy Adult Volunteers


Clinical Trial Description

Subjects will undergo a Screening period beginning up to 14 days prior to enrollment, the vaccination(s) will be administered on Day 0, pre- and post-dose assessment, follow-up visits, and an end of study (EOS) or early termination (ET) visit (as applicable). Subjects will be enrolled prior to vaccination on Day 0, to one (1) of two (2) treatment groups. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05188469
Study type Interventional
Source EyeGene Inc.
Contact Daeun Kim
Phone +8223221687
Email [email protected]
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date February 1, 2022
Completion date December 1, 2023

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05049226 - Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine Phase 2
Recruiting NCT05097053 - A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19 Phase 4
Recruiting NCT04691947 - Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC Phase 1
Completed NCT04546841 - Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults Phase 1
Recruiting NCT04566276 - ChulaCov19 Vaccine in Healthy Adults Phase 1/Phase 2
Completed NCT04915820 - Iron and COVID-19 Vaccine Response N/A
Recruiting NCT04898946 - Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong
Not yet recruiting NCT05198596 - A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above Phase 3
Recruiting NCT04764422 - Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand Phase 1/Phase 2
Recruiting NCT04838080 - Safety and Immunogenicity of the Inactivated Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine Compared to Placebo Phase 1
Recruiting NCT04830800 - A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC Phase 1/Phase 2
Recruiting NCT04884776 - Modulation of Gut Microbiota to Enhance Health and Immunity N/A
Recruiting NCT05012800 - Safety and Immunogenicity of COVID-19 Vaccine Administered in Older Adults Phase 4
Recruiting NCT04910971 - Quantification of Binding and Neutralizing Antibody Levels in COVID-19 Vaccinated Health Care Workers Over 1 Year
Not yet recruiting NCT05197153 - A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19 Phase 2
Completed NCT05004740 - Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1c
Recruiting NCT04784689 - Host Immune Response to Novel RNA COVID-19 Vaccination
Not yet recruiting NCT05197712 - A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, and Reactogenicity of the Baiya SARS-CoV-2 Vax 2 Vaccine in Healthy Adults Phase 1
Not yet recruiting NCT04751695 - Oxidative Stress Parameters, Trace Element and Quality of Life in Men Before and After Covid-19 Vaccines N/A
Not yet recruiting NCT04751721 - Oxidative Stress Parameters, Trace Element and Quality of Life in Women Before and After Covid-19 Vaccines N/A